ClinicalTrials.gg
CompletedNCT04540627Updated Oct 4, 2021Results posted

Exploratory Study to Estimate the Prophylactic Efficacy of Palivizumab in Healthy Adult Participants Inoculated With RSV

A Phase 1 interventional study of Palivizumab and Placebo in Healthy Adult Participants, sponsored by mAbxience Research S.L.. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-10-04.

Sponsored by mAbxience Research S.L. (part of Fresenius Kabi) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

Double-Blind, Randomised, Placebo-Controlled Exploratory Study to Estimate the Prophylactic Efficacy of Palivizumab in Healthy Adult Participants Inoculated with Respiratory Syncytial Virus (RSV).

Read the detailed description

As no data exists for Palivizumab in the RSV human challenge model, this exploratory study is therefore planned to establish the margins of effect and variance of prophylactically administered Palivizumab within the RSV-A Memphis 37b challenge model in healthy adult volunteers.

The study will be performed in adults aged 18-55 years, in two parts.

  • Part 1: All participants will be administered Palivizumab (8mg/Kg, intravenously). Pharmacokinetic (PK), safety will be measured.

If there are no safety concerns in Part 1, and PK analysis of Palivizumab treated participants confirm the modelling of 8mg/Kg to be appropriate, Part 2 will commence with the planned 8mg/Kg treatment dose. However, if PK analysis of Part 1 suggests that 8mg/kg may be insufficient dose to provide suitable efficacious coverage in Part 2, then Part 2 will proceed with a dose of 15mg/Kg.

  • Part 2: Participants will be either administered Palivizumab (8mg/Kg or 15mg/Kg, as determined in Part ) or a placebo and they will subsequently be challenged with an RSV-A strain (Memphis 37b). The margin of effect and variance between groups will be measured, as well as safety and reactogenicity.
02

Conditions studied

  • Healthy Adult Participants
03

In context

Lead sponsor

mAbxience Research S.L. is the lead sponsor of 15 studies on the registry; 1 is open to participants now.

First submitted before mAbxience Research S.L. became part of Fresenius Kabi.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. An document signed and dated by the participant and the Investigator.
  2. Aged between 18 and 55 years old on the day of signing the consent form.
  3. In good health with no history, or current evidence, of medical conditions, and no clinically significant test abnormalities that will interfere with participant safety, as defined by medical history, physical examination, (including vital signs), (ECG), and routine laboratory tests as determined by the Investigator.
  4. A documented medical history prior to enrolment.
  5. The following criteria are applicable to female participants participating in the study.

    1. Females of must have a negative pregnancy test prior to enrolment.
    2. Females of non-childbearing potential:

    <!-- -->

    1. Post- menopausal females; defined as having a history of amenorrhea for >12 months with no alternative medical cause, and /or by Follicle stimulating hormone (FSH) level >40mIU/mL, confirmed by laboratory
    2. Documented status as being surgically sterile (e.g. tubal ligation, hysterectomy, bilateral salpingectomy and bilateral oophorectomy).
  6. The following criteria apply to female and male participants:

    1. Female participants of childbearing potential must use one form of highly effective . Hormonal methods must be in place from at least 2 weeks prior to the first study visit. The contraception use must continue until 30 days after the date of viral challenge/last dosing with IMP (whichever occurs last). Highly effective contraception is as described below:

    <!-- -->

    1. Established use of hormonal methods of contraception described below (for a minimum of 2 weeks prior to the first study visit). When hormonal methods of contraception are used, male partners are required to use a condom with a spermicide:
  1. Oral 2. Intravaginal 3. Transdermal b. Intrauterine device (IUD) c. Intrauterine hormone-releasing system (IUS) d. Bilateral tubal ligation e. Male sterilisation (with the appropriate post vasectomy documentation of the absence of sperm in the ejaculate) where the vasectomised male is the sole partner for that woman.

f. True abstinence - sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the participant.

b) Male participants must agree to the contraceptive requirements below at entry to quarantine and continuing until 90 days after the date of Viral challenge / last dosing with the medicinal product (IMP) (whichever occurs last):

  1. Use a condom with a spermicide to prevent pregnancy in a female partner or to prevent exposure of any partner (male and female) to the IMP.
  2. Male sterilisation with the appropriate post vasectomy documentation of the absence of sperm in the ejaculate (please note that the use of condom with spermicide will still be required to prevent partner exposure). This applies only to males participating in the study
  3. In addition, for female partners of childbearing potential, that partner must use another form of contraception such as one of the highly effective methods mentioned above for female participants.
  4. True abstinence - sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the participant.

c) In addition to the contraceptive requirements above, male participants must agree not to donate sperm following discharge from quarantine until 90 days after the date of Viral Challenge/last dosing with IMP (whichever occurs last).

  1. For Part 2 of the study: Sero-suitable to the challenge virus, as defined in the study Analytical Plan.

Exclusion criteria

Exclusion Criteria:

Medical History

  1. History of, or currently active, symptoms or signs suggestive of upper or lower respiratory tract infection within 4 weeks prior to the first study visit.
  2. a) Any history or evidence of any other or currently active systemic comorbidities including psychiatric disorders (includes participants with a history of depression and/or anxiety).

    b) And/or other major disease that, in the opinion of the Investigator, may put the participant at undue risk, or interfere with a participant completing the study and necessary investigations.

    The following conditions apply:

    • Participants with clinically mild atopic eczema/atopic dermatitis and clinically mild psoriasis may be included at the Investigator's discretion (e.g., if small amounts of regular topical are used, no eczema in cubital fossa; moderate to large amounts of daily dermal corticosteroids is an exclusion).
    • Rhinitis (including hay fever) which is clinically active or history of moderate to severe rhinitis, or history of seasonal allergic rhinitis likely to be active at the time of inclusion into the study and/or requiring regular nasal corticosteroids on an at least weekly basis, within 30 days of admission to quarantine will be excluded. Participants with a history of currently inactive rhinitis (within the last 30 days) or mild rhinitis may be included at the PI's discretion.
    • Participants with a physician diagnosed underactive thyroid who have been controlled on treatment for at least 6 months with evidence of a normal thyroid function test (TFT) can be included at the discretion of the PI.
    • Any concurrent serious illness including history of that may interfere with the aims of the study or a participant completing the study. Basal cell carcinoma within 5 years of initial diagnosis or with evidence of recurrence is also an exclusion.

      o Participants with a history of psychiatric illness including depression and/or anxiety of any severity within the last 2 years can be included if the Patient Health Questionnaire (PHQ-9) and / or the Generalised Anxiety Disorder Questionnaire (GAD-7) is less than or equal to 4. Participants with a PHQ-9 or GAD-7 score of between 5 and 9 may be included following consultation with a Senior Physician (Clinical Lead for Screening) who may advise further consultation with the PI.

      o Participants reporting physician diagnosed migraine can be included provided there are no associated neurological symptoms such as hemiplegia or visual loss. Cluster headache/migraine or prophylactic treatment for migraine is an exclusion.

      • Participants with physician diagnosed mild Irritable Bowel Syndrome (IBS) not requiring regular treatment can be included at the discretion of the PI.
  3. Participants who have smoked ≥ 10 pack years at any time [10 pack years is equivalent to one pack of 20 cigarettes a day for 10 years]).
  4. A total body weight ≤ 50 kg and (BMI) ≤18 kg/m2 and ≥30kg/m2
  5. Females who:

    1. Are breastfeeding, or
    2. Have been pregnant within 6 months prior to the study.
  6. History of anaphylaxis-and/or a history of severe allergic reaction or significant intolerance to any food or drug, as assessed by the PI.
  7. Venous access deemed inadequate for the phlebotomy and cannulation demands of the study.
  8. a) For Part 2 of the study: Any significant abnormality altering the anatomy of the nose in a substantial way or nasopharynx that may interfere with the aims of the study and in particular any of the nasal assessments or viral challenge, (historical nasal polyps can be included, but large nasal polyps causing current and significant symptoms and/or requiring regular treatments in the last month will be excluded).

    b) Any clinically significant history of epistaxis (large nosebleeds) within the last 3 months of the first study visit and/or history of being hospitalized due to epistaxis on any previous occasion.

    c) Any nasal or sinus surgery within 3 months of the first study visit. Prior or Concomitant Medications and Assessments

  9. For Part 2 of the study:

    1. Evidence of vaccinations within the 4 weeks prior to the planned date of viral challenge/first dosing with IMP (whichever occurs first).
    2. Intention to receive any vaccination(s) before the last day of Follow-up. (NB. No travel restrictions will apply after the Day 28 (±3 days) Follow-up Visit).
  10. Receipt of blood or blood products, or loss (including blood donations) of 470 mL or more of blood during the 3 months prior to the planned date of viral challenge/first dosing with IMP (whichever occurs first) or planned during the 3 months after the final visit.
  11. a) Receipt of any drug within 3 months prior to the planned date of viral challenge/first dosing with IMP (whichever occurs first).

    b) Receipt of three or more investigational drugs within the previous 12 months prior to the planned date of viral challenge/first dosing with IMP (whichever occurs first).

    For Part 2 of the study:

    c) Prior inoculation with a virus from the same virus-family as the challenge virus.

    d) Prior participation in another human viral challenge study with a respiratory virus in the preceding 3 months, taken from the date of viral challenge in the previous study to the date of expected viral challenge in this study

  12. a) Confirmed positive test for drugs of abuse on first study visit. One repeat test allowed at PI discretion.

    b) History or presence of alcohol addiction, or excessive use of alcohol (weekly intake in excess of 28 units alcohol; 1 unit being a half glass of beer, a small glass of wine or a measure of spirits), or excessive consumption of xanthine containing substances (e.g. daily intake in excess of 5 cups of caffeinated drinks e.g. coffee, tea, cola).

  13. For Part 2 of the study:

    A (FEV1) \< 80%.

  14. Positive (HIV), active hepatitis A (HAV), B (), or C () test.

    Other

  15. Those employed or immediate relatives of those employed at hVIVO or the Sponsor.
  16. Any other finding that, in the opinion of the Investigator, deems the participant unsuitable for the study.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
56 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Sodium Chloride 0.9% Solution (Normal Saline)

    Drug: Placebo · Other: RSV-A Memphis 37b virus

  • Active comparator
    Palivizumab (Synagis™)

    Sterile vial 50mg/0.5mL

    Drug: Palivizumab · Other: RSV-A Memphis 37b virus

Interventions

  • Liquid solution in sterile water for injection (final concentration of 20mg/mL), intravenous infusion, single dose of 8mg/kg or 15mg/kg, administered at a rate of 1mL/min

    Also known as: Synagis™

  • DrugPlacebo

    Sodium Chloride 0.9% Solution (Normal Saline), intravenous infusion, single dose of 0mg/Kg, administered at a rate of 1mL/min

  • OtherRSV-A Memphis 37b virus

    Single Intranasal Virus Dose (challenge dose is approximately 4.5log10 PFU)

06

What researchers measure

Primary outcomes

  1. Mean Serum Concentrations (Cmax) for Open-label Palivizumab (Part 1) on Day 12.

    The PK assessment up to and including Day 12 exposure was used as a decision information for the dose to be given to participants in Part 2. Pharmacokinetic exposure data from at least 5 out of 6 participants were required for dose decision making with a projected exposure of ≥40 μg/mL on Day 12 according to the protocol. This was achieved after administration of a single IV dose of Palivizumab at 8 mg/kg. Therefore, a dose of 8 mg/kg was chosen for Part 2.

    Time frame: In Part 1: before the start of infusion; at end of infusion,15 minutes and 0.5, 1, 4, 8, and 12 hours after infusion; and at 1, 2, 3, 7, and 12 days after infusion.

  2. Area Under the Viral Load-time Curve (VL-AUC) as Determined by Polymerase Chain Reaction (qRT-PCR) on Nasal Samples, for Double-blind Palivizumab or Placebo (Part 2).

    RSV viral load of RSV-A Memphis 37b as determined by qRT-PCR on nasal samples collected twice daily: Assessment of the Area under the viral load-time curve (VL-AUC)

    Time frame: From two days post viral challenge (Day 2) to the end of quarantine (Day 12) in Part 2 on nasal samples collected twice daily.

  3. qRT-PCR Peak Viral Load for Double-blind Palivizumab or Placebo (Part 2).

    Peak viral load of RSV-A Memphis 37b as determined by qRT-PCR on nasal samples collected twice daily.

    Time frame: From two days post viral challenge (Day 2) to the end of quarantine (Day 12) in Part 2

Secondary outcomes

  1. Area Under the Viral Load-time Curve (VL-AUC) as Determined by Cell Culture on Nasal Samples, for Double-blind Palivizumab (Part 2).

    RSV Viral Load of RSV-A Memphis 37b as Determined by Cell Culture on Nasal Samples collected twice daily: Area under the viral load-time curve (VL-AUC) of RSV-A Memphis 37b

    Time frame: From two days post viral challenge (Day 2) to the end of quarantine (Day 12) in Part 2 on nasal samples collected twice daily.

  2. Cell Culture Peak Viral Load for Double-blind Palivizumab or Placebo (Part 2).

    Peak Viral Load of RSV-A Memphis 37b as Determined by Cell Culture on Nasal Sample

    Time frame: From Day 2 to Day 12 in Part 2

  3. Number of Participants With Laboratory-confirmed Infection of RSV-A Memphis 37b in Nasal Samples (Variant 1) for Double-blind Palivizumab or Placebo (Part 2).

    Percentage of Participants Infected Post-viral Challenge (Infectivity Status and Rate): occurrence of at least 2 positive "quantifiable" qRT-PCR measurements in nasal samples. Laboratory-confirmed infection (variant 1): At least 2 positive quantifiable detections by viral load qRT-PCR assay specific for the challenge virus, reported within 4 consecutive scheduled assessments and from 2 independent samples from Day 2 until discharge and/or 1 positive detection by viral load qRT-PCR assay, specific for the challenge virus, in which an aliquot of the same sample has also tested positive in a viral culture assay appropriate for detecting the challenge virus from Day 2 until discharge.

    Time frame: From Day 2 to Day 12 in Part 2

  4. Number of Participants With Laboratory-confirmed Infection of RSV-A Memphis 37b in Nasal Samples (Variant 2), for Double-blind Palivizumab or Placebo (Part 2).

    Percentage of Participants Infected Post-viral Challenge (Infectivity Status and Rate): Occurrence of at least 2 positive "detectable" qRT-PCR measurements in nasal samples. Laboratory-confirmed infection (variant 2): At least 2 positive detectable assessments by viral load qRT-PCR assay specific for the challenge virus, reported within 4 consecutive scheduled assessments and from 2 independent samples from Day 2 until discharge and/or 1 positive detection by viral load qRT-PCR assay, specific for the challenge virus, in which an aliquot of the same sample has also tested positive in a viral culture assay appropriate for detecting the challenge virus from Day 2 until discharge.

    Time frame: From Day 2 to Day 12 in Part 2

  5. Viral Shedding of RSV-A Memphis 37b in Nasal Samples in Terms of Duration, for Double-blind Palivizumab or Placebo (Part 2).

    Estimation of the duration of viral shedding by the number of days with quantifiable qRT-PCR measurements in nasal samples starting 2 days post viral challenge (Day 2) up to the end of quarantine.

    Time frame: From Day 2 to Day 12 in Part 2

  6. Viral Shedding of RSV-A Memphis 37b in Nasal Samples in Terms of Time to Peak Viral Load, for Double-blind Palivizumab or Placebo (Part 2).

    Estimation of the duration of viral shedding by the time to peak viral load of RSV by quantifiable qRT-PCR.

    Time frame: From Day 2 to Day 12 in Part 2

  7. Viral Shedding of RSV-A Memphis 37b in Nasal Samples in Terms of Peak Viral Load, for Double-blind Palivizumab or Placebo (Part 2).

    Peak viral load of RSV-A Memphis 37b as defined by the maximum viral load determined by quantifiable qRT PCR measurements in nasal samples starting 2 days post viral challenge (Day 2) up to the end of quarantine.

    Time frame: From Day 2 to Day 12 in Part 2

  8. Total Symptom Score (TSS)-Time Curve (AUC) Collected Daily in the Participant Symptom Diary Card

    Mean TSS values (collected daily in the symptom diary card) over time. Symptoms were collected using the hVIVO (services provider) symptom diary card. Several symptoms (such as runny nose, sore throat, earache, etc) in the 13-item questionnaire were graded on a scale of 0-3 (grade 0: No symptoms; grade 1: just noticeable; grade 2: clearly bothersome from time to time but does not interfere with me doing my normal daily activities; grade 3: Quite bothersome most or all of the time, and it stops me participating in activities). Shortness of breath and wheeze have an additional grade 4: Symptoms at rest. The total symptom score (TSS) was determined as the sum of the symptom scores ranging from 0.0 (min) to 41(max) \[or a maximum of 41x11.33=464.67 depending on what the reviewer is asking\] using a 13-items self-reported diary card. 11.33 is the number of days symptom diary cards were included (Day +1 morning dairy card to Day 12 morning diary card). Higher scores mean worse outcome.

    Time frame: From two days post viral challenge (Day 2) to the end of quarantine (Day 12) in Part 2 on nasal samples collected twice daily.

  9. Peak Symptom Scores

    Peak symptom scores for symptoms collected daily in the participant symptom diary card. Symptoms (such as runny nose, sore throat, earache, etc) were collected using the 13-item hVIVO symptom questionnaire and were graded on a scale of 0-3 (grade 0: No symptoms; grade 1: just noticeable; grade 2: clearly bothersome from time to time but does not interfere with me doing my normal daily activities; grade 3: Quite bothersome most or all of the time, and it stops me participating in activities). Shortness of breath and wheeze have an additional grade 4: Symptoms at rest. The total symptom score (TSS) was determined as the sum of the symptom scores ranging from 0.0 (min) to 41(max) \[or a maximum of 41x11.33=464.67 depending on what the reviewer is asking\] using a 13-items self-reported diary card. 11.33 is the number of days symptom diary cards were included (Day +1 morning dairy card to Day 12 morning diary card). Higher scores mean worse outcome.

    Time frame: From Day 2 to Day 12 in Part 2

  10. Total Weight of Nasal Discharge Produced

    Nasal Discharge Collection from Paper Tissues by means of the total weight of nasal discharge produced.

    Time frame: From Day 1 to Day 12 in Part 2

  11. Total Number of Tissues Used by Participants

    Nasal Discharge Collection from Paper Tissues by means of the total number of tissues used.

    Time frame: From Day 1 to Day 12 in Part 2

  12. Number of Participants With Laboratory-confirmed Virus-like Illness (Variant 1) Using Viral Shedding Variant 1, for Double-blind Palivizumab or Placebo (Part 2).

    Illness Post-viral challenge measured by means of the proportion of participants with any symptom ≥grade 1 for the evaluable population.

    Time frame: From Day 2 to Day 12 in Part 2

  13. The Occurrence of Laboratory-confirmed Virus-like Illness (Variant 1) Using Viral Shedding Variant 2, for Double-blind Palivizumab or Placebo (Part 2).

    Illness Post-viral challenge measured by means of the proportion of participants with any symptom ≥grade 1 for the evaluable population.

    Time frame: From Day 2 to Day 12 in Part 2

  14. The Occurrence of Laboratory-confirmed Virus-like Illness (Variant 2) Using Viral Shedding Variant 1, for Double-blind Palivizumab or Placebo (Part 2).

    Illness Post-viral challenge measured by means of the proportion of participants with any symptom ≥grade 1 for the evaluable population.

    Time frame: From Day 2 to Day 12 in Part 2

  15. The Occurrence of Laboratory-confirmed Virus-like Illness (Variant 2) Using Viral Shedding Variant 2, for Double-blind Palivizumab or Placebo (Part 2).

    Illness Post-viral challenge measured by means of the proportion of participants with any symptom ≥grade 1 for the evaluable population.

    Time frame: From Day 2 to Day 12 in Part 2

  16. Cmax

    Evaluation of Palivizumab PK levels throughout the study, by means of Cmax after intravenous administration of Palivizumab.

    Time frame: Before the start of infusion; at end of infusion, 15 minutes and 0.5, 1, 4, 8, and 12 hours after infusion; and at 1, 2, 3, 7 and 12 days after infusion (Part 1) or at 1, 2, 3, 7, 13, 21, and 29 days after infusion (Part 2)

  17. Tmax

    Palivizumab PK levels throughout the study, by means of Tmax after intravenous administration of Palivizumab.

    Time frame: Before the start of infusion; at end of infusion, 15 minutes and 0.5, 1, 4, 8, and 12 hours after infusion; and at 1, 2, 3, 7, and 12 days after infusion (Part 1) or at 1, 2, 3, 7, 13, 21, and 29 days after infusion (Part 2)

  18. Safety Adults: Number of Participants With Adverse Events (AEs)

    Incidence of AEs, treatment-emergent AEs (TEAEs), serious AEs (SAEs) and; drug-related or challenge-virus related TEAEs and SAEs

    Time frame: From Day 1 to Day 18 in Part 1 and from Day 1 to Day 28 in Part 2

  19. Immunogenicity: Number of Participants Positive for Anti-palivizumab Antibody (ADA)

    Determination of the incidence of anti-palivizumab ADA (number and percent of participants tested positive for anti-palivizumab ADA). ADA positive participant: baseline negative and any sample after treatment positive, or baseline positive and titre increased 4- to 9-fold after treatment) before the dose of palivizumab and at scheduled post-dose assessments.

    Time frame: Part 2: prior to infusion with Palivizumab and 7, 13, and 29 days post Palivizumab infusion.

07

Results

Posted Oct 4, 2021

Participant flow

Open-label Treatment: PK Sentinel
Participant flow — Open-label Treatment: PK Sentinel
MilestoneOpen-label Palivizumab (Part 1)Double-blind Placebo (Part 2)Double-blind Palivizumab (Synagis™) (Part 2)
Started600
Completed600
Not completed000
Double-blind Treatment: Viral Challenge
Participant flow — Double-blind Treatment: Viral Challenge
MilestoneOpen-label Palivizumab (Part 1)Double-blind Placebo (Part 2)Double-blind Palivizumab (Synagis™) (Part 2)
Started02525
Completed02525
Not completed000

Outcome measures

PrimaryMean Serum Concentrations (Cmax) for Open-label Palivizumab (Part 1) on Day 12.

The PK assessment up to and including Day 12 exposure was used as a decision information for the dose to be given to participants in Part 2. Pharmacokinetic exposure data from at least 5 out of 6 participants were required for dose decision making with a projected exposure of ≥40 μg/mL on Day 12 according to the protocol. This was achieved after administration of a single IV dose of Palivizumab at 8 mg/kg. Therefore, a dose of 8 mg/kg was chosen for Part 2.

Time frame:
In Part 1: before the start of infusion; at end of infusion,15 minutes and 0.5, 1, 4, 8, and 12 hours after infusion; and at 1, 2, 3, 7, and 12 days after infusion.
Reported as:
Mean · μg/mL
Mean Serum Concentrations (Cmax) for Open-label Palivizumab (Part 1) on Day 12.
μg/mLOpen-label Palivizumab (Part 1)Double-blind Placebo (Part 2)Double-blind Palivizumab (Synagis™) (Part 2)
Mean Serum Concentrations (Cmax) for Open-label Palivizumab (Part 1) on Day 12.71.2 ± 6.11——
PrimaryArea Under the Viral Load-time Curve (VL-AUC) as Determined by Polymerase Chain Reaction (qRT-PCR) on Nasal Samples, for Double-blind Palivizumab or Placebo (Part 2).

RSV viral load of RSV-A Memphis 37b as determined by qRT-PCR on nasal samples collected twice daily: Assessment of the Area under the viral load-time curve (VL-AUC)

Time frame:
From two days post viral challenge (Day 2) to the end of quarantine (Day 12) in Part 2 on nasal samples collected twice daily.
Reported as:
Mean · Log10 copies*day/mL
Area Under the Viral Load-time Curve (VL-AUC) as Determined by Polymerase Chain Reaction (qRT-PCR) on Nasal Samples, for Double-blind Palivizumab or Placebo (Part 2).
Log10 copies*day/mLDouble-blind Placebo (Part 2)Double-blind Palivizumab (Synagis™) (Part 2)
Area Under the Viral Load-time Curve (VL-AUC) as Determined by Polymerase Chain Reaction (qRT-PCR) on Nasal Samples, for Double-blind Palivizumab or Placebo (Part 2).11.68 ± 15.369.94 ± 12.38
Statistical analysis
  • Double-blind Placebo (Part 2) vs Double-blind Palivizumab (Synagis™) (Part 2) · Wilcoxon (Mann-Whitney) · p = 0.5802
PrimaryqRT-PCR Peak Viral Load for Double-blind Palivizumab or Placebo (Part 2).

Peak viral load of RSV-A Memphis 37b as determined by qRT-PCR on nasal samples collected twice daily.

Time frame:
From two days post viral challenge (Day 2) to the end of quarantine (Day 12) in Part 2
Reported as:
Mean · Log10 copies/mL
qRT-PCR Peak Viral Load for Double-blind Palivizumab or Placebo (Part 2).
Log10 copies/mLDouble-blind Placebo (Part 2)Double-blind Palivizumab (Synagis™) (Part 2)
qRT-PCR Peak Viral Load for Double-blind Palivizumab or Placebo (Part 2).3.66 ± 2.423.11 ± 2.65
Statistical analysis
  • Double-blind Placebo (Part 2) vs Double-blind Palivizumab (Synagis™) (Part 2) · Wilcoxon (Mann-Whitney) · p = 0.4868
SecondaryArea Under the Viral Load-time Curve (VL-AUC) as Determined by Cell Culture on Nasal Samples, for Double-blind Palivizumab (Part 2).

RSV Viral Load of RSV-A Memphis 37b as Determined by Cell Culture on Nasal Samples collected twice daily: Area under the viral load-time curve (VL-AUC) of RSV-A Memphis 37b

Time frame:
From two days post viral challenge (Day 2) to the end of quarantine (Day 12) in Part 2 on nasal samples collected twice daily.
Reported as:
Mean · Log10 PFU*day/mL
Area Under the Viral Load-time Curve (VL-AUC) as Determined by Cell Culture on Nasal Samples, for Double-blind Palivizumab (Part 2).
Log10 PFU*day/mLDouble-blind Placebo (Part 2)Double-blind Palivizumab (Synagis™) (Part 2)
Area Under the Viral Load-time Curve (VL-AUC) as Determined by Cell Culture on Nasal Samples, for Double-blind Palivizumab (Part 2).2.05 ± 5.291.64 ± 3.43
Statistical analysis
  • Double-blind Placebo (Part 2) vs Double-blind Palivizumab (Synagis™) (Part 2) · Wilcoxon (Mann-Whitney) · p = 0.2681
SecondaryCell Culture Peak Viral Load for Double-blind Palivizumab or Placebo (Part 2).

Peak Viral Load of RSV-A Memphis 37b as Determined by Cell Culture on Nasal Sample

Time frame:
From Day 2 to Day 12 in Part 2
Reported as:
Mean · Log10 PFU/mL
Cell Culture Peak Viral Load for Double-blind Palivizumab or Placebo (Part 2).
Log10 PFU/mLDouble-blind Placebo (Part 2)Double-blind Palivizumab (Synagis™) (Part 2)
Cell Culture Peak Viral Load for Double-blind Palivizumab or Placebo (Part 2).0.60 ± 1.470.88 ± 1.41
Statistical analysis
  • Double-blind Placebo (Part 2) vs Double-blind Palivizumab (Synagis™) (Part 2) · Wilcoxon (Mann-Whitney) · p = 0.2431
SecondaryNumber of Participants With Laboratory-confirmed Infection of RSV-A Memphis 37b in Nasal Samples (Variant 1) for Double-blind Palivizumab or Placebo (Part 2).

Percentage of Participants Infected Post-viral Challenge (Infectivity Status and Rate): occurrence of at least 2 positive "quantifiable" qRT-PCR measurements in nasal samples. Laboratory-confirmed infection (variant 1): At least 2 positive quantifiable detections by viral load qRT-PCR assay specific for the challenge virus, reported within 4 consecutive scheduled assessments and from 2 independent samples from Day 2 until discharge and/or 1 positive detection by viral load qRT-PCR assay, specific for the challenge virus, in which an aliquot of the same sample has also tested positive in a viral culture assay appropriate for detecting the challenge virus from Day 2 until discharge.

Time frame:
From Day 2 to Day 12 in Part 2
Reported as:
Count of participants · Participants
Number of Participants With Laboratory-confirmed Infection of RSV-A Memphis 37b in Nasal Samples (Variant 1) for Double-blind Palivizumab or Placebo (Part 2).
ParticipantsDouble-blind Placebo (Part 2)Double-blind Palivizumab (Synagis™) (Part 2)
Number of Participants With Laboratory-confirmed Infection of RSV-A Memphis 37b in Nasal Samples (Variant 1) for Double-blind Palivizumab or Placebo (Part 2).1312
SecondaryNumber of Participants With Laboratory-confirmed Infection of RSV-A Memphis 37b in Nasal Samples (Variant 2), for Double-blind Palivizumab or Placebo (Part 2).

Percentage of Participants Infected Post-viral Challenge (Infectivity Status and Rate): Occurrence of at least 2 positive "detectable" qRT-PCR measurements in nasal samples. Laboratory-confirmed infection (variant 2): At least 2 positive detectable assessments by viral load qRT-PCR assay specific for the challenge virus, reported within 4 consecutive scheduled assessments and from 2 independent samples from Day 2 until discharge and/or 1 positive detection by viral load qRT-PCR assay, specific for the challenge virus, in which an aliquot of the same sample has also tested positive in a viral culture assay appropriate for detecting the challenge virus from Day 2 until discharge.

Time frame:
From Day 2 to Day 12 in Part 2
Reported as:
Count of participants · Participants
Number of Participants With Laboratory-confirmed Infection of RSV-A Memphis 37b in Nasal Samples (Variant 2), for Double-blind Palivizumab or Placebo (Part 2).
ParticipantsDouble-blind Placebo (Part 2)Double-blind Palivizumab (Synagis™) (Part 2)
Number of Participants With Laboratory-confirmed Infection of RSV-A Memphis 37b in Nasal Samples (Variant 2), for Double-blind Palivizumab or Placebo (Part 2).1515
SecondaryViral Shedding of RSV-A Memphis 37b in Nasal Samples in Terms of Duration, for Double-blind Palivizumab or Placebo (Part 2).

Estimation of the duration of viral shedding by the number of days with quantifiable qRT-PCR measurements in nasal samples starting 2 days post viral challenge (Day 2) up to the end of quarantine.

Time frame:
From Day 2 to Day 12 in Part 2
Reported as:
Mean · days
Viral Shedding of RSV-A Memphis 37b in Nasal Samples in Terms of Duration, for Double-blind Palivizumab or Placebo (Part 2).
daysDouble-blind Placebo (Part 2)Double-blind Palivizumab (Synagis™) (Part 2)
Viral Shedding of RSV-A Memphis 37b in Nasal Samples in Terms of Duration, for Double-blind Palivizumab or Placebo (Part 2).2.84 ± 3.012.61 ± 2.98
SecondaryViral Shedding of RSV-A Memphis 37b in Nasal Samples in Terms of Time to Peak Viral Load, for Double-blind Palivizumab or Placebo (Part 2).

Estimation of the duration of viral shedding by the time to peak viral load of RSV by quantifiable qRT-PCR.

Time frame:
From Day 2 to Day 12 in Part 2
Reported as:
Mean · days
Viral Shedding of RSV-A Memphis 37b in Nasal Samples in Terms of Time to Peak Viral Load, for Double-blind Palivizumab or Placebo (Part 2).
daysDouble-blind Placebo (Part 2)Double-blind Palivizumab (Synagis™) (Part 2)
Viral Shedding of RSV-A Memphis 37b in Nasal Samples in Terms of Time to Peak Viral Load, for Double-blind Palivizumab or Placebo (Part 2).7.21 ± 2.987.03 ± 2.35
SecondaryViral Shedding of RSV-A Memphis 37b in Nasal Samples in Terms of Peak Viral Load, for Double-blind Palivizumab or Placebo (Part 2).

Peak viral load of RSV-A Memphis 37b as defined by the maximum viral load determined by quantifiable qRT PCR measurements in nasal samples starting 2 days post viral challenge (Day 2) up to the end of quarantine.

Time frame:
From Day 2 to Day 12 in Part 2
Reported as:
Mean · Log10 copies/mL
Viral Shedding of RSV-A Memphis 37b in Nasal Samples in Terms of Peak Viral Load, for Double-blind Palivizumab or Placebo (Part 2).
Log10 copies/mLDouble-blind Placebo (Part 2)Double-blind Palivizumab (Synagis™) (Part 2)
Viral Shedding of RSV-A Memphis 37b in Nasal Samples in Terms of Peak Viral Load, for Double-blind Palivizumab or Placebo (Part 2).3.66 ± 2.423.11 ± 2.65
Statistical analysis
  • Double-blind Placebo (Part 2) vs Double-blind Palivizumab (Synagis™) (Part 2) · Wilcoxon (Mann-Whitney) · p = 0.4868
SecondaryTotal Symptom Score (TSS)-Time Curve (AUC) Collected Daily in the Participant Symptom Diary Card

Mean TSS values (collected daily in the symptom diary card) over time. Symptoms were collected using the hVIVO (services provider) symptom diary card. Several symptoms (such as runny nose, sore throat, earache, etc) in the 13-item questionnaire were graded on a scale of 0-3 (grade 0: No symptoms; grade 1: just noticeable; grade 2: clearly bothersome from time to time but does not interfere with me doing my normal daily activities; grade 3: Quite bothersome most or all of the time, and it stops me participating in activities). Shortness of breath and wheeze have an additional grade 4: Symptoms at rest. The total symptom score (TSS) was determined as the sum of the symptom scores ranging from 0.0 (min) to 41(max) \[or a maximum of 41x11.33=464.67 depending on what the reviewer is asking\] using a 13-items self-reported diary card. 11.33 is the number of days symptom diary cards were included (Day +1 morning dairy card to Day 12 morning diary card). Higher scores mean worse outcome.

Time frame:
From two days post viral challenge (Day 2) to the end of quarantine (Day 12) in Part 2 on nasal samples collected twice daily.
Reported as:
Mean · Total Symptom Score scale-points*day
Total Symptom Score (TSS)-Time Curve (AUC) Collected Daily in the Participant Symptom Diary Card
Total Symptom Score scale-points*dayDouble-blind Placebo (Part 2)Double-blind Palivizumab (Synagis™) (Part 2)
Total Symptom Score (TSS)-Time Curve (AUC) Collected Daily in the Participant Symptom Diary Card13.84 ± 14.727.27 ± 9.03
SecondaryPeak Symptom Scores

Peak symptom scores for symptoms collected daily in the participant symptom diary card. Symptoms (such as runny nose, sore throat, earache, etc) were collected using the 13-item hVIVO symptom questionnaire and were graded on a scale of 0-3 (grade 0: No symptoms; grade 1: just noticeable; grade 2: clearly bothersome from time to time but does not interfere with me doing my normal daily activities; grade 3: Quite bothersome most or all of the time, and it stops me participating in activities). Shortness of breath and wheeze have an additional grade 4: Symptoms at rest. The total symptom score (TSS) was determined as the sum of the symptom scores ranging from 0.0 (min) to 41(max) \[or a maximum of 41x11.33=464.67 depending on what the reviewer is asking\] using a 13-items self-reported diary card. 11.33 is the number of days symptom diary cards were included (Day +1 morning dairy card to Day 12 morning diary card). Higher scores mean worse outcome.

Time frame:
From Day 2 to Day 12 in Part 2
Reported as:
Mean · score on a scale
Peak Symptom Scores
score on a scaleDouble-blind Placebo (Part 2)Double-blind Palivizumab (Synagis™) (Part 2)
Peak Symptom Scores4.16 ± 3.452.54 ± 3.32
Statistical analysis
  • Double-blind Placebo (Part 2) vs Double-blind Palivizumab (Synagis™) (Part 2) · Wilcoxon (Mann-Whitney) · p = 0.0403
SecondaryTotal Weight of Nasal Discharge Produced

Nasal Discharge Collection from Paper Tissues by means of the total weight of nasal discharge produced.

Time frame:
From Day 1 to Day 12 in Part 2
Reported as:
Mean · g
Total Weight of Nasal Discharge Produced
gDouble-blind Placebo (Part 2)Double-blind Palivizumab (Synagis™) (Part 2)
Total Weight of Nasal Discharge Produced22.23 ± 41.527.66 ± 14.92
SecondaryTotal Number of Tissues Used by Participants

Nasal Discharge Collection from Paper Tissues by means of the total number of tissues used.

Time frame:
From Day 1 to Day 12 in Part 2
Reported as:
Mean · tissues
Total Number of Tissues Used by Participants
tissuesDouble-blind Placebo (Part 2)Double-blind Palivizumab (Synagis™) (Part 2)
Total Number of Tissues Used by Participants32.04 ± 42.7420.38 ± 21.88
SecondaryNumber of Participants With Laboratory-confirmed Virus-like Illness (Variant 1) Using Viral Shedding Variant 1, for Double-blind Palivizumab or Placebo (Part 2).

Illness Post-viral challenge measured by means of the proportion of participants with any symptom ≥grade 1 for the evaluable population.

Time frame:
From Day 2 to Day 12 in Part 2
Reported as:
Count of participants · Participants
Number of Participants With Laboratory-confirmed Virus-like Illness (Variant 1) Using Viral Shedding Variant 1, for Double-blind Palivizumab or Placebo (Part 2).
ParticipantsDouble-blind Placebo (Part 2)Double-blind Palivizumab (Synagis™) (Part 2)
Number of Participants With Laboratory-confirmed Virus-like Illness (Variant 1) Using Viral Shedding Variant 1, for Double-blind Palivizumab or Placebo (Part 2).115
SecondaryThe Occurrence of Laboratory-confirmed Virus-like Illness (Variant 1) Using Viral Shedding Variant 2, for Double-blind Palivizumab or Placebo (Part 2).

Illness Post-viral challenge measured by means of the proportion of participants with any symptom ≥grade 1 for the evaluable population.

Time frame:
From Day 2 to Day 12 in Part 2
Reported as:
Count of participants · Participants
The Occurrence of Laboratory-confirmed Virus-like Illness (Variant 1) Using Viral Shedding Variant 2, for Double-blind Palivizumab or Placebo (Part 2).
ParticipantsDouble-blind Placebo (Part 2)Double-blind Palivizumab (Synagis™) (Part 2)
The Occurrence of Laboratory-confirmed Virus-like Illness (Variant 1) Using Viral Shedding Variant 2, for Double-blind Palivizumab or Placebo (Part 2).115
SecondaryThe Occurrence of Laboratory-confirmed Virus-like Illness (Variant 2) Using Viral Shedding Variant 1, for Double-blind Palivizumab or Placebo (Part 2).

Illness Post-viral challenge measured by means of the proportion of participants with any symptom ≥grade 1 for the evaluable population.

Time frame:
From Day 2 to Day 12 in Part 2
Reported as:
Count of participants · Participants
The Occurrence of Laboratory-confirmed Virus-like Illness (Variant 2) Using Viral Shedding Variant 1, for Double-blind Palivizumab or Placebo (Part 2).
ParticipantsDouble-blind Placebo (Part 2)Double-blind Palivizumab (Synagis™) (Part 2)
The Occurrence of Laboratory-confirmed Virus-like Illness (Variant 2) Using Viral Shedding Variant 1, for Double-blind Palivizumab or Placebo (Part 2).1311
SecondaryThe Occurrence of Laboratory-confirmed Virus-like Illness (Variant 2) Using Viral Shedding Variant 2, for Double-blind Palivizumab or Placebo (Part 2).

Illness Post-viral challenge measured by means of the proportion of participants with any symptom ≥grade 1 for the evaluable population.

Time frame:
From Day 2 to Day 12 in Part 2
Reported as:
Count of participants · Participants
The Occurrence of Laboratory-confirmed Virus-like Illness (Variant 2) Using Viral Shedding Variant 2, for Double-blind Palivizumab or Placebo (Part 2).
ParticipantsDouble-blind Placebo (Part 2)Double-blind Palivizumab (Synagis™) (Part 2)
The Occurrence of Laboratory-confirmed Virus-like Illness (Variant 2) Using Viral Shedding Variant 2, for Double-blind Palivizumab or Placebo (Part 2).1514
SecondaryCmax

Evaluation of Palivizumab PK levels throughout the study, by means of Cmax after intravenous administration of Palivizumab.

Time frame:
Before the start of infusion; at end of infusion, 15 minutes and 0.5, 1, 4, 8, and 12 hours after infusion; and at 1, 2, 3, 7 and 12 days after infusion (Part 1) or at 1, 2, 3, 7, 13, 21, and 29 days after infusion (Part 2)
Reported as:
Mean · μg/mL
Cmax
μg/mLOpen-label Palivizumab (Part 1)Double-blind Placebo (Part 2)Double-blind Palivizumab (Synagis™) (Part 2)
Cmax262 ± 35.6—283 ± 46.5
SecondaryTmax

Palivizumab PK levels throughout the study, by means of Tmax after intravenous administration of Palivizumab.

Time frame:
Before the start of infusion; at end of infusion, 15 minutes and 0.5, 1, 4, 8, and 12 hours after infusion; and at 1, 2, 3, 7, and 12 days after infusion (Part 1) or at 1, 2, 3, 7, 13, 21, and 29 days after infusion (Part 2)
Reported as:
Median · hours
Tmax
hoursOpen-label Palivizumab (Part 1)Double-blind Placebo (Part 2)Double-blind Palivizumab (Synagis™) (Part 2)
Tmax0.90 (0.57 to 1.70)—0.92 (0.53 to 1.77)
SecondarySafety Adults: Number of Participants With Adverse Events (AEs)

Incidence of AEs, treatment-emergent AEs (TEAEs), serious AEs (SAEs) and; drug-related or challenge-virus related TEAEs and SAEs

Time frame:
From Day 1 to Day 18 in Part 1 and from Day 1 to Day 28 in Part 2
Reported as:
Number · participants
Safety Adults: Number of Participants With Adverse Events (AEs)
participantsOpen-label Palivizumab (Part 1)Double-blind Placebo (Part 2)Double-blind Palivizumab (Synagis™) (Part 2)
Any AE01214
Any TEAE01214
Any TEAE related to the study drug014
Any TEAE related to the challenge virus058
Any SAE001
Any SAE leading to study discontinuation000
Any SAE related to the study treatment000
Any SAE related to the challenge virus001
Any death000
SecondaryImmunogenicity: Number of Participants Positive for Anti-palivizumab Antibody (ADA)

Determination of the incidence of anti-palivizumab ADA (number and percent of participants tested positive for anti-palivizumab ADA). ADA positive participant: baseline negative and any sample after treatment positive, or baseline positive and titre increased 4- to 9-fold after treatment) before the dose of palivizumab and at scheduled post-dose assessments.

Time frame:
Part 2: prior to infusion with Palivizumab and 7, 13, and 29 days post Palivizumab infusion.
Reported as:
Count of participants · Participants
Immunogenicity: Number of Participants Positive for Anti-palivizumab Antibody (ADA)
ParticipantsDouble-blind Palivizumab (Synagis™) (Part 2)
Immunogenicity: Number of Participants Positive for Anti-palivizumab Antibody (ADA)0

Adverse events

Collected over Day 1 to Day 28. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Double-blind Placebo (Part 2)0/25 (0%)0/25 (0%)12/25 (48%)
Double-blind Palivizumab (Synagis™) (Part 2)0/25 (0%)1/25 (4%)14/25 (56%)
Most frequent serious events
Most frequent serious events
EventDouble-blind Placebo (Part 2)Double-blind Palivizumab (Synagis™) (Part 2)
MyocarditisCardiac disorders0/251/25
Most frequent other events
Most frequent other events
EventDouble-blind Placebo (Part 2)Double-blind Palivizumab (Synagis™) (Part 2)
Alanine Aminotransferase IncreasedInvestigations6/259/25
Aspartate aminotransferase increasedInvestigations4/255/25
RashSkin and subcutaneous tissue disorders0/252/25
Back PainMusculoskeletal and connective tissue disorders2/250/25

Baseline characteristics

Age, Continuous
Age, Continuous(years)Open-label Palivizumab (Part 1)Double-blind Placebo (Part 2)Double-blind Palivizumab (Synagis™) (Part 2)Total
Mean25.67 ± 2.5828.16 ± 6.3026.76 ± 5.8326.86 ± 4.90
Sex: Female, Male
Sex: Female, Male(Participants)Open-label Palivizumab (Part 1)Double-blind Placebo (Part 2)Double-blind Palivizumab (Synagis™) (Part 2)Total
Female212519
Male4132037
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Open-label Palivizumab (Part 1)Double-blind Placebo (Part 2)Double-blind Palivizumab (Synagis™) (Part 2)Total
American Indian or Alaska Native0011
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American0022
White4232047
More than one race2226
Unknown or Not Reported0000
08

Study locations

1 site
  • hVIVO Services Limited
    London, E1 2AX, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2020 to primary completion in Oct 2020, 3 months.

Results were first posted in Oct 2021, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2020
First posted
Sep 7, 2020
StartActual
Jul 6, 2020
Primary completionActual
Oct 23, 2020
CompletionActual
Oct 23, 2020
Results first posted
Oct 4, 2021
Last update
Oct 4, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 4, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04540627
Responsible party
Sponsor
First posted
Sep 7, 2020
Start date
Jul 6, 2020
Primary completion
Oct 23, 2020
Completion
Oct 23, 2020
Results posted
Oct 4, 2021
Last update
Oct 4, 2021

Study contacts

Sungeen Hill, MD
principal investigator · hVIVO Services Limited

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Palivizumab

Start the discussion